Clinical Trial

A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is to evaluate the tolerability and safety of ONO-7428 in participants with unresectable advanced or recurrent solid tumors.
Protocol Amendment History 3 changes
critical Enrollment closed, study ongoing 2026-08-06
notable Enrollment reduced: 60 -> 35 participants 2026-08-06
notable Sponsor changed: Ono Pharmaceutical Co. Ltd -> Ono Pharmaceutical Co., Ltd. 2026-04-19
Trial Details
NCT Number NCT06816108
Lead Sponsor Ono Pharmaceutical Co., Ltd.
Conditions Solid Tumor, NSCLC
Enrollment 35 participants
Start Date 2025-04-21
Primary Completion 2029-07 (estimated)
Study Completion 2029-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-05